Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

Mark G. Lebwohl, MD, explains what causes generalized pustular psoriasis (GPP) and the potential triggers for GPP episodes. Ryan Haumschild, PharmD, MS, MBA: Dr Lebwohl, you gave us a great overview.

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...

Imsidolimab is an investigational humanized IgG4 antibody that inhibits the function of the interleukin-36 receptor. Findings from two phase 3 trials showed skin clearance was achieved and maintained ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Spesolimab exhibited rapid control of generalized ...

The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...

Please provide your email address to receive an email when new articles are posted on . Imsidolimab yielded a response rate of 75% at 16 weeks in patients with generalized pustular psoriasis. No ...

Many patients with generalized pustular psoriasis (GPP) flares got no specific treatment for them, despite their high risk of severe complications, according to the biggest study of these episodes to ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to ...